This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Athenex Rallies on Positive Early Data on Psoriasis Candidate
by Zacks Equity Research
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
by Zacks Equity Research
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.
Emergent (EBS) Wins HHS Contract to Supply VIGIV Product
by Zacks Equity Research
Shares of Emergent (EBS) rise after the company gets a 10-year HHS contract valued at roughly $535 million to dispense VIGIV product to the U.S. government for supporting its smallpox awareness drive.
Celldex Presents Data From CDX-3379 Study at ASCO, Stock Down
by Zacks Equity Research
Celldex (CLDX) presents updated data on CDX-3379 and Erbitux combination regimen, which supports further development in biomarker selected patient population.
Acorda (ACOR) Down 11.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Epizyme's NDA for Tazemetostat Eyes Epithelioid Sarcoma Cure
by Zacks Equity Research
Epizyme (EPZM) submits an NDA filing for tazemetostat to the FDA with an objective to treat patients suffering metastatic epithelioid sarcoma, not eligible for curative surgery. Shares inch up.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
by Zacks Equity Research
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%
by Zacks Equity Research
Chiasma (CHMA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 42.27% and 20.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Acorda Therapeutics (ACOR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda to Gain From Inbrija Sales and Neurological Pipeline
by Zacks Equity Research
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
Acorda (ACOR) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda Therapeutics (ACOR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day.
Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.
Acorda Therapeutics (ACOR) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Acorda (ACOR) delivered earnings and revenue surprises of 175.00% and 70.38%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Array BioPharma (ARRY) Soars: Stock Adds 11% in Session
by Zacks Equity Research
Array BioPharma (ARRY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Is Acorda Therapeutics (ACOR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ACOR) Outperforming Other Medical Stocks This Year?
Vertex Terminates COO Ian Smith on Code of Conduct Violation
by Zacks Equity Research
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.